Scarica l'app Stockscreener
10.84
3.99%
-0.45
Dopo l'orario di chiusura:
10.99
0.15
+1.38%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BHVN Giù?
Forum
Previsione
Precedente Chiudi:
$11.29
Aprire:
$11.37
Volume 24 ore:
2.11M
Relative Volume:
0.56
Capitalizzazione di mercato:
$1.44B
Reddito:
-
Utile/perdita netta:
$-766.97M
Rapporto P/E:
-1.4151
EPS:
-7.66
Flusso di cassa netto:
$-646.43M
1 W Prestazione:
-2.78%
1M Prestazione:
+22.76%
6M Prestazione:
-26.56%
1 anno Prestazione:
-70.92%
Intervallo 1D:
$10.65
$11.46
Intervallo di 1 settimana:
$10.29
$11.72
Portata 52W:
$7.48
$44.28
Biohaven Ltd Stock (BHVN) Company Profile
Nome
Biohaven Ltd
Settore
Industria
Telefono
203-404-0410
Indirizzo
215 CHURCH STREET, NEW HAVEN, CT
Confronta BHVN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
10.84 | 1.50B | 0 | -766.97M | -646.43M | -7.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-03 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-11-26 | Downgrade | UBS | Buy → Neutral |
| 2025-11-06 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2025-11-05 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-09-17 | Iniziato | Citigroup | Buy |
| 2025-09-03 | Iniziato | Raymond James | Strong Buy |
| 2025-05-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-09-16 | Iniziato | Jefferies | Buy |
| 2024-09-04 | Iniziato | Bernstein | Outperform |
| 2024-07-24 | Iniziato | Morgan Stanley | Overweight |
| 2024-02-16 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-02-06 | Iniziato | UBS | Buy |
| 2023-12-22 | Iniziato | H.C. Wainwright | Buy |
| 2023-12-08 | Iniziato | Robert W. Baird | Outperform |
| 2023-01-24 | Iniziato | SVB Securities | Outperform |
| 2023-01-04 | Iniziato | JP Morgan | Overweight |
| 2022-12-02 | Iniziato | BTIG Research | Buy |
| 2022-10-26 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2022-10-12 | Iniziato | Piper Sandler | Overweight |
| 2022-08-19 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-08-08 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-05-11 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-19 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-08-10 | Downgrade | UBS | Buy → Neutral |
| 2021-08-03 | Reiterato | Canaccord Genuity | Buy |
| 2021-03-11 | Iniziato | UBS | Buy |
| 2020-12-15 | Iniziato | H.C. Wainwright | Buy |
| 2020-04-17 | Iniziato | Cowen | Outperform |
| 2020-02-10 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2019-11-22 | Iniziato | Wedbush | Outperform |
| 2019-06-25 | Reiterato | Canaccord Genuity | Buy |
| 2019-05-06 | Iniziato | Goldman | Buy |
| 2019-04-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-03-04 | Reiterato | Needham | Buy |
| 2018-07-03 | Reiterato | Needham | Buy |
| 2018-07-02 | Reiterato | Needham | Buy |
| 2018-04-05 | Downgrade | Barclays | Overweight → Equal Weight |
| 2018-02-22 | Reiterato | Canaccord Genuity | Buy |
| 2017-12-15 | Iniziato | Canaccord Genuity | Buy |
| 2017-10-03 | Reiterato | Needham | Buy |
Mostra tutto
Biohaven Ltd Borsa (BHVN) Ultime notizie
The Bull Case For Biohaven (BHVN) Could Change Following BHV-7000 MDD Trial Halt And R&D Pivot - Yahoo! Finance Canada
Outlook Therapeutics, Intelligent Bio Solutions And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Risk Check: Why Biohaven Ltd stock attracts global investorsLong Setup & Fast Exit and Entry Strategy Plans - moha.gov.vn
Breakout Move: Why Biohaven Ltd stock attracts global investorsJuly 2025 Catalysts & Low Drawdown Momentum Ideas - moha.gov.vn
Wall Street analysts predict an 88.57% upside in Biohaven Ltd. (BHVN): Here's what you should know - MSN
Biohaven reports Phase 2 depression trial results - Indian Pharma Post
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Novavax (NVAX), Xenon (XENE) and Biohaven Ltd. (BHVN) - The Globe and Mail
(BHVN) Risk Channels and Responsive Allocation - Stock Traders Daily
Biohaven (NYSE:BHVN) Trading 3.6% HigherHere's What Happened - MarketBeat
Analysts Conflicted on These Healthcare Names: Xenon (XENE) and Biohaven Ltd. (BHVN) - The Globe and Mail
Biohaven Shares Rally as Promising Cancer Data Unveiled - StocksToTrade
Biohaven Reports Promising Results for Cancer Treatment, Faces Setback in Depression Therapy - StocksToTrade
Biohaven’s BHV-1510 Promising Cancer Data Fuels Market Anticipation - timothysykes.com
Biohaven Emerges Strong Amid Promising Cancer Drug Data - timothysykes.com
Key facts: Biohaven Ltd. develops BHV-7000 for epilepsy; J.P. Morgan reports poor trial results - TradingView — Track All Markets
What's Going On With Biohaven Stock Friday? - Benzinga
Biohaven (NYSE:BHVN) Shares Gap DownWhat's Next? - MarketBeat
Biohaven Ltd. (BHVN): A High-Stakes Clinical Crossroad in Neuroscience and Immunology - FinancialContent
Biohaven Stock Gaps Lower on Failed Phase 2 Drug Trial - Schaeffer's Investment Research
US Stocks Mixed; Biohaven Shares Fall - Sahm
Watch Nvidia Up on AI Licensing Deal, Biohaven Down on Study Results, Coforge Up - Bloomberg.com
Stock Market Today: Dow Jones, S&P 500, Nasdaq Futures Decline After Christmas Day—Nvidia, Sobr Safe, Biohaven In Focus (UPDATED) - Benzinga
Stock Market Today: Dow Jones, S&P 500, Nasdaq Futures Decline After Christmas Day—Nvidia, Sobr Safe, Biohaven In Focus (UPDATED) - Benzinga
Cautiously Bullish After Biohaven’s Cash Runway And Dilution Risk Rise (NYSE:BHVN) - Seeking Alpha
Stock Movers: Nvidia, Coforge, Biohaven - Bloomberg.com
Stifel reiterates Buy rating on Xenon Pharmaceuticals stock amid competitor setback - Investing.com
Biohaven Misses The Mark In Depression Trial, Stock Falls - Benzinga
H.C. Wainwright maintains Biohaven stock at Neutral after MDD trial failure - Investing.com Nigeria
Biohaven, Omeros And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Biohaven stock defended despite trial setback (BHVN:NYSE) - Seeking Alpha
Stock market today: Dow Jones, S&P 500 futures slip after Christmas Day—Nvidia, Sobr Safe, Biohaven in focus - MSN
Stock Market Today: Dow Jones, S&P 500 Futures Slip After Christmas Day—Nvidia, Sobr Safe, Biohaven In Focus - Sahm
Why Davis Commodities Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket - Benzinga
Nvidia, Sobr Safe And 3 Stocks To Watch Heading Into Friday - Benzinga
Analysts Are Neutral on Top Healthcare Stocks: Biohaven Ltd. (BHVN), Omeros (OMER) - The Globe and Mail
Biohaven (BHVN) Valuation Check After BHV-1510 Cancer Data and BHV-7000 Pipeline Shift - simplywall.st
Biohaven Shares Dive: Time to Reflect? - StocksToTrade
Biohaven’s depression drug misses primary endpoint in Phase 2 study By Investing.com - Investing.com Nigeria
Biohaven's depression drug fails mid-stage trial, shares fall - marketscreener.com
Biohaven Stock Slumps After Hours As Failed Depression Study Adds To A Brutal 2025 — Retail Eyes Epilepsy And Obesity Catalysts - Stocktwits
Biohaven Provides Update From Phase 2 Proof-of-Concept Study wit - GuruFocus
Biohaven (NYSE:BHVN) Stock Price Down 13%What's Next? - MarketBeat
Biohaven’s depression drug misses primary endpoint in Phase 2 study - Investing.com India
Biohaven stock falls after depression drug misses primary endpoint By Investing.com - Investing.com Nigeria
Biohaven falls as depression candidate fails in phase 2 - Seeking Alpha
Biohaven stock falls after depression drug misses primary endpoint - Investing.com
Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder - PR Newswire
Wall Street Analysts Predict an 88.57% Upside in Biohaven Ltd. (BHVN): Here's What You Should Know - Yahoo Finance
Biohaven Ltd. Provides Update from Phase 2 Proof-Of-Concept Study with Bhv-7000 in Major Depressive Disorder - marketscreener.com
Stock Watch: What Biohaven Can Teach Us About Optimism And Reality - Citeline News & Insights
Aug Weekly: Will Biohaven Ltd stock benefit from upcoming earnings reports - moha.gov.vn
Biohaven Ltd Azioni (BHVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):